Research and Markets: Geron's Imetelstat for myelofibrosis

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/rktlzk/gerons) has announced the addition of the "Geron's Imetelstat for myelofibrosis" report to their offering.

Geron is developing the telomerase inhibitor, imetelstat, for the treatment of myelofibrosis (MF), a rare, chronic bone marrow malignancy disorder in which patients produce an excess of progenitor blood cells of myeloid (bone marrow) lineage. Imetelstat directly inhibits telomerase activity by binding with high affinity to the RNA template of telomerase. Telomerase stabilizes telomeres and extends the lifetime of tumor cells inhibition in tumor cells leads to telomere shortening which, after sufficient cell divisions, results in apoptosis (cell death).

Without the ability to maintain telomere length, the cancer cell eventually stops growing and dies. Malignant cells also lose cell adhesion properties after exposure to the drug. Imetelstat is lipid soluble, so it does not require a membrane transporter for cellular uptake.

Key Topics Covered:

Introduction

  • MYELOFIBROSIS a MYELOPROLIFERATIVE NEOPLASM
  • Clinical picture of myelofibrosis
  • Disease mechanisms in MF
  • Current treatments of MF imetelstat
  • A primer on telomeres and telomerase
  • Imetelstat's mechanism of action
  • Phase I trials of imetelstat
  • Phase II studies in solid tumors disappointed
  • Phase II trial in essential thrombocythemia
  • Investigator-sponsored phase II study in MF showed impressive results
  • Next steps for imetelstat

Clinical and regulatory Discussion

  • How good are the imetelstat results in MF compared with those of Jakafi?
  • Jakafi does not induce complete bone marrow remissions
  • The effect of chemotherapy on bone marrow fibrosis
  • Why does imetelstat work in some tumors and not in others?
  • Regulatory discussion
  • Additional safety risks may emerge
  • Geron could pursue a number of different strategies

Market opportunity

  • Overview: Jakafi is first to market for MF
  • Epidemiology of MF
  • Pipeline in MF
  • Imetelstat seems well positioned to compete for market share in MF.
  • Revenue projections

Summary opinion

Companies Mentioned:

  • Acceleron
  • AstraZeneca
  • Celgene
  • Cell Therapeutics Inc/Baxter
  • Cephalon
  • Cephalon
  • Eisai
  • Eli Lilly
  • Gilead
  • Italfarmaco
  • KaloBios
  • MEI Pharma
  • Merck
  • Novartis
  • Promedior
  • Roche
  • Sanofi
  • Takeda
  • Vernalis/Novartis

For more information visit http://www.researchandmarkets.com/research/rktlzk/gerons

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals